BioAge Labs, Inc. (BIOA) SEC Filings & Earnings Calls

Clinical trial risk; no efficacy/safety data yet; topline results not expected until H2 2027.

“Topline results expected in the second half of 2027” · word for word

Clinical-stage biotech with no approved products; net loss increasing as R&D spend rises

“Net loss was $26.1 million; R&D expenses increased $4.6M YoY”

Dependence on BGE-102 program success; pipeline concentration risk

“BGE-102 program costs driving R&D increase; azelaprag terminated”

Clinical development risk

“We have not generated any product revenue to date.”

Litigation risk

“On January 7, 2025, a putative securities class action complaint was filed against the Company and certain of its officers and directors” · word for word

Dilution risk

“In January 2026, the Company completed an underwritten public offering of its common stock, issuing 5,897,435 shares at a public offering price of $19.50 per share for net proceeds of $107.4 million” · word for word

Clinical trial failure risk

“The Company's product candidates require approvals from the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals.” · word for word

Financing risk

“If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts.”

Litigation risk

“On March 27, 2026, the plaintiff filed a notice of appeal of the Court's order granting defendants' motion to dismiss.” · word for word

No product revenue

“The Company has not generated any product revenue to date.” · word for word

Customer concentration

“As of March 31, 2026 and December 31, 2025, one customer accounted for 100% of the Company's accounts receivable. For the three months ended March 31, 2026 and 2025, the same customer accounted for 100% of the Company's revenue.” · word for word

Clinical-stage biotech with no approved products; net loss increasing as R&D spend rises

“Net loss was $22.3 million; R&D expenses increased $9.3M YoY”

Dependence on BGE-102 program success; pipeline concentration risk

“BGE-102 program costs driving R&D increase; azelaprag terminated”

Pre-revenue biotechnology company with no approved products or revenue from product sales

“No revenue from product sales is disclosed; the company is a clinical-stage biotechnology company.”

Dependence on clinical trial success and regulatory approval

“Corporate performance objectives included certain development goals and milestones, indicating reliance on pipeline progress.” · word for word

Insider trading policy change may reduce transparency

“In April 2026, our Board of Directors amended and restated the Insider Trading Policy to remove the automatic quarterly blackout periods such that we will rely on special blackouts.” · word for word

Clinical trial failure risk

“We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.” · word for word

Regulatory approval risk

“the timing of and our ability to obtain and maintain regulatory approvals” · word for word

Financing risk

“the sufficiency of our cash, cash equivalents and marketable securities” · word for word

Competition risk

“Given the resulting activity and investment of pharmaceutical companies in the therapeutic area” · word for word

Commercialization risk

“our commercialization, marketing and manufacturing capabilities and strategy” · word for word

Clinical-stage biopharma with no approved products; reliance on pipeline success and regulatory approvals

“Company is a clinical-stage biopharmaceutical company; no mention of approved products or revenue”

Dilution from new share issuance.

“5,897,435 shares issued; additional 884,615 option shares.”

Clinical-stage biotech with no approved products; forward-looking statements caution.

“Company's ability to develop, obtain regulatory approval for and commercialize its product candidates.” · word for word

Clinical trial risk: DME trial results not expected until mid-2027; early-stage data may not predict later success.

“Forward-looking statements caution that positive early results may not be replicated in later trials.”

Regulatory and competitive risk: FDA priorities may shift; other NLRP3 inhibitors in development.

“Risk factors include regulatory changes and competition.”

Clinical trial risk: positive Phase 1 data may not replicate in later-stage trials; Phase 2a not yet initiated.

“Forward-looking statements caution that positive results in early trials may not be predictive of later results.”

Regulatory and competitive risk: NLRP3 inhibitor space is competitive; FDA approval uncertain.

“Risk factors mention regulatory approval uncertainties and competition.”

Clinical trial risks remain; data is interim and full analysis pending in 1H26.

“full analysis to follow after database lock and unblinding in the first half of 2026” · word for word

Clinical trial failure risk

“The Company's lead product candidate, BGE-102, is in Phase 1 clinical trials; failure could significantly impact the company.” · word for word

Cash burn risk

“Net cash used in operating activities: ($53,376) for nine months ended September 30, 2025.”

Regulatory approval risk

“The Company's product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales.” · word for word

Dilution risk

“To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of its existing stockholders may be diluted.” · word for word

Competition risk

“The Company faces competition from larger companies with more resources in the obesity drug market.”

Clinical-stage biotech with no approved products; net loss of $20.2M in Q3 2025.

“Net loss was $20.2 million for the quarter ended September 30, 2025” · word for word